Caroline S. Foo

4.8k total citations
17 papers, 799 citations indexed

About

Caroline S. Foo is a scholar working on Infectious Diseases, Molecular Biology and Organic Chemistry. According to data from OpenAlex, Caroline S. Foo has authored 17 papers receiving a total of 799 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 6 papers in Molecular Biology and 3 papers in Organic Chemistry. Recurrent topics in Caroline S. Foo's work include SARS-CoV-2 and COVID-19 Research (8 papers), Cancer therapeutics and mechanisms (6 papers) and COVID-19 Clinical Research Studies (6 papers). Caroline S. Foo is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (8 papers), Cancer therapeutics and mechanisms (6 papers) and COVID-19 Clinical Research Studies (6 papers). Caroline S. Foo collaborates with scholars based in Belgium, United States and Switzerland. Caroline S. Foo's co-authors include Stewart T. Cole, Jérémie Piton, Andréanne Lupien, Johan Neyts, Rana Abdelnabi, Birgit Weynand, Piet Maes, Steven De Jonghe, Anthony Vocat and Kévin Pethe and has published in prestigious journals such as Nature Communications, Journal of Virology and The Journal of Infectious Diseases.

In The Last Decade

Caroline S. Foo

17 papers receiving 787 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Caroline S. Foo Belgium 14 572 312 184 106 98 17 799
Naveen Vankadari Australia 10 651 1.1× 278 0.9× 71 0.4× 22 0.2× 122 1.2× 22 958
Han Cheng United States 20 360 0.6× 318 1.0× 344 1.9× 55 0.5× 52 0.5× 42 967
Lisa Evans DeWald United States 14 496 0.9× 176 0.6× 220 1.2× 44 0.4× 15 0.2× 18 760
Carina Stiller Germany 6 363 0.6× 232 0.7× 99 0.5× 43 0.4× 34 0.3× 9 643
Yunru Yang China 11 357 0.6× 277 0.9× 44 0.2× 27 0.3× 30 0.3× 19 624
Veronica Soloveva United States 18 319 0.6× 355 1.1× 181 1.0× 56 0.5× 41 0.4× 34 915
Jitendra Kumar Chaudhary India 9 238 0.4× 154 0.5× 30 0.2× 33 0.3× 32 0.3× 34 516
Nabab Khan United States 18 262 0.5× 238 0.8× 200 1.1× 8 0.1× 46 0.5× 35 781
Min-Han Lin Taiwan 10 325 0.6× 156 0.5× 33 0.2× 21 0.2× 44 0.4× 14 522
Meena Sachdeva United States 16 377 0.7× 259 0.8× 217 1.2× 34 0.3× 32 0.3× 22 858

Countries citing papers authored by Caroline S. Foo

Since Specialization
Citations

This map shows the geographic impact of Caroline S. Foo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline S. Foo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline S. Foo more than expected).

Fields of papers citing papers by Caroline S. Foo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline S. Foo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline S. Foo. The network helps show where Caroline S. Foo may publish in the future.

Co-authorship network of co-authors of Caroline S. Foo

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline S. Foo. A scholar is included among the top collaborators of Caroline S. Foo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline S. Foo. Caroline S. Foo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Sharma, Sapna, Thomas Vercruysse, Lorena Sánchez-Felipe, et al.. (2022). Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters. Nature Communications. 13(1). 6644–6644. 12 indexed citations
2.
Cafferty, Séan Mc, A.K.M. Ashiqul Haque, Nathalie R. Le François, et al.. (2022). A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity. Molecular Therapy. 30(9). 2968–2983. 40 indexed citations
3.
Abdelnabi, Rana, Caroline S. Foo, Xin Zhang, et al.. (2022). The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. Antiviral Research. 198. 105253–105253. 65 indexed citations
4.
Abdelnabi, Rana, Caroline S. Foo, Dirk Jochmans, et al.. (2022). The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nature Communications. 13(1). 719–719. 84 indexed citations
5.
Abdelnabi, Rana, Caroline S. Foo, Suzanne J. F. Kaptein, et al.. (2022). A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection. Journal of Virology. 96(16). e0075822–e0075822. 6 indexed citations
6.
Foo, Caroline S., Rana Abdelnabi, Laura Vangeel, et al.. (2022). Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model. Microorganisms. 10(3). 633–633. 4 indexed citations
7.
Persoons, Leentje, Evelien Vanderlinden, Laura Vangeel, et al.. (2021). Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues. Antiviral Research. 193. 105127–105127. 35 indexed citations
8.
Abdelnabi, Rana, Robbert Boudewijns, Caroline S. Foo, et al.. (2021). Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. EBioMedicine. 68. 103403–103403. 67 indexed citations
9.
Abdelnabi, Rana, Caroline S. Foo, Steven De Jonghe, et al.. (2021). Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. The Journal of Infectious Diseases. 224(5). 749–753. 92 indexed citations
10.
Lupien, Andréanne, Caroline S. Foo, Svetlana Savina, et al.. (2020). New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in Mycobacterium tuberculosis. PLoS Pathogens. 16(1). e1008270–e1008270. 35 indexed citations
11.
Foo, Caroline S., Kévin Pethe, & Andréanne Lupien. (2020). Oxidative Phosphorylation—an Update on a New, Essential Target Space for Drug Discovery in Mycobacterium tuberculosis. Applied Sciences. 10(7). 2339–2339. 37 indexed citations
12.
Piton, Jérémie, Anthony Vocat, Andréanne Lupien, et al.. (2018). Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 62(10). 52 indexed citations
13.
Lupien, Andréanne, Anthony Vocat, Caroline S. Foo, et al.. (2018). Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169). Antimicrobial Agents and Chemotherapy. 62(11). 52 indexed citations
14.
Foo, Caroline S., Andréanne Lupien, Anthony Vocat, et al.. (2018). Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis. mBio. 9(5). 54 indexed citations
15.
Piton, Jérémie, Caroline S. Foo, & Stewart T. Cole. (2016). Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors. Drug Discovery Today. 22(3). 526–533. 64 indexed citations
16.
Foo, Caroline S., Benoît Lechartier, Gaëlle S. Kolly, et al.. (2016). Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 60(11). 6451–6459. 40 indexed citations
17.
Tsika, Elpida, Caroline S. Foo, Dustin Dikeman, et al.. (2014). Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiology of Disease. 71. 345–358. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naveen Vankadari Breakdown of academic impact, for papers by Han Cheng Breakdown of academic impact, for papers by Lisa Evans DeWald Breakdown of academic impact, for papers by Carina Stiller Breakdown of academic impact, for papers by Yunru Yang Breakdown of academic impact, for papers by Veronica Soloveva Breakdown of academic impact, for papers by Jitendra Kumar Chaudhary Breakdown of academic impact, for papers by Nabab Khan Breakdown of academic impact, for papers by Min-Han Lin Breakdown of academic impact, for papers by Meena Sachdeva
Rankless by CCL
2026